New Two-Drug attack on blood cancer shows promise in trial
NCT ID NCT07199296
Summary
This study is testing a combination of two drugs, orelabrutinib and rituximab, for people newly diagnosed with a type of blood cancer called mantle cell lymphoma (MCL). The main goal is to see how well this treatment can put the cancer into complete remission. Researchers will also track how long patients stay cancer-free and monitor the safety of the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA (MCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
RECRUITINGShanghai, 200025, China
Conditions
Explore the condition pages connected to this study.